{"id":"gsk3862995b","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, GSK3862995B reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"GSK3862995B is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:05.667Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07201051","phase":"PHASE2","title":"A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-09-26","conditions":"Bronchiectasis","enrollment":400},{"nctId":"NCT06154837","phase":"PHASE1","title":"A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":130},{"nctId":"NCT06979518","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK3862995B","genericName":"GSK3862995B","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK3862995B is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}